The ClinGen Evidence Repository is an **FDA-recognized human genetic variant database** containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]

Variant: NM_001126112.2(TP53):c.329G>C (p.Arg110Pro)

Version: 1.0

CA10580948

233627 (ClinVar)

Gene: TP53 (HGNC:7157)
Condition: Li-Fraumeni syndrome (MONDO:0018875)
Inheritance Mode: Autosomal dominant inheritance
UUID: b7f8a84e-5a46-4d96-b19e-9b58d882b2b6
Approved on: 2025/6/5
Published on: 2025/7/18

HGVS expressions

NM_001126112.2(TP53):c.329G>C (p.Arg110Pro)
NM_001126112.2:c.329G>C
NC_000017.11:g.7676040C>G
CM000679.2:g.7676040C>G
NC_000017.10:g.7579358C>G
CM000679.1:g.7579358C>G
NC_000017.9:g.7520083C>G
NG_017013.2:g.16511G>C
ENST00000503591.2:c.329G>C
ENST00000508793.6:c.329G>C
ENST00000509690.6:c.-21-804G>C
ENST00000514944.6:c.96+342G>C
ENST00000604348.6:c.329G>C
ENST00000269305.9:c.329G>C
ENST00000269305.8:c.329G>C
ENST00000359597.8:c.329G>C
ENST00000413465.6:c.329G>C
ENST00000420246.6:c.329G>C
ENST00000445888.6:c.329G>C
ENST00000455263.6:c.329G>C
ENST00000503591.1:c.329G>C
ENST00000505014.5:n.585G>C
ENST00000508793.5:c.329G>C
ENST00000509690.5:c.-21-804G>C
ENST00000514944.5:c.96+342G>C
ENST00000604348.5:c.329G>C
ENST00000610292.4:c.212G>C
ENST00000610538.4:c.212G>C
ENST00000615910.4:c.329G>C
ENST00000617185.4:c.329G>C
ENST00000619485.4:c.212G>C
ENST00000620739.4:c.212G>C
ENST00000622645.4:c.212G>C
ENST00000635293.1:c.212G>C
NM_000546.5:c.329G>C
NM_001126113.2:c.329G>C
NM_001126114.2:c.329G>C

NM_001126118.1:c.212G>C
NM_001276695.1:c.212G>C
NM_001276696.1:c.212G>C
NM_001276760.1:c.212G>C
NM_001276761.1:c.212G>C
NM_001276695.2:c.212G>C
NM_001276696.2:c.212G>C
NM_001276760.2:c.212G>C
NM_001276761.2:c.212G>C
NM_000546.6:c.329G>C
NM_001126112.3:c.329G>C
NM_001126113.3:c.329G>C
NM_001126114.3:c.329G>C
NM_001126118.2:c.212G>C
NM_001276695.3:c.212G>C
NM_001276696.3:c.212G>C
NM_001276760.3:c.212G>C
NM_001276761.3:c.212G>C

Pathogenic

Met criteria codes 5

PS4_Supporting PS3 PM2_Supporting PS2_Moderate PM1

Not Met criteria codes 13

PS1 BP4 BP2 PP1 PP3 PP4 PM6 PM5 BA1 BS2 BS1 BS4 BS3

Evidence Links 0

Expert Panel

TP53 VCEP

Criteria Specification Information

Criteria Specification: *ClinGen TP53 Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for TP53 Version 2.3.0*

Criteria Specification Approval History

Criteria Specifications for this VCEP

Evidence submitted by expert panel

TP53 VCEP

The NM_000546.6: c.329G>C variant in TP53 is a missense variant predicted to cause substitution of arginine by proline at amino acid 110 (p.Arg110Pro). This variant has been reported in 2 unrelated families meeting Revised Chompret criteria and reported in 1 individual under the age of 40 diagnosed with a HER2+ breast cancer. Based on this evidence, this variant scores 1.5 total points meeting the TP53 VCEP phenotype scoring criteria of 1-1.5 points. (PS4_Supporting; PMIDs: 30455982, 23894400; Internal lab contributors). This variant has been identified as a de novo occurrence with confirmed parental relationships in 1 individual with a moderately LFS-associated cancer totaling 2 phenotype points (PS2_Moderate; PMID: 29070607). This variant is absent from gnomAD v4.1.0 (PM2_Supporting). In vitro assays performed in yeast and/or human cell lines showed non-functional transactivation and loss of growth suppression activity indicating that this variant impacts protein function (PS3; PMIDs: 12826609, 30224644, 29979965). This variant has 11 somatic occurrences for the same amino acid change in cancerhotspots.org (v2) sufficient to be defined as a mutational hotspot by the Clingen TP53 VCEP (≥ 10 somatic occurrences, PMID: 30311369) (PM1). In summary, this variant meets the criteria to be classified as Pathogenic for Li Fraumeni syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen TP53 VCEP: PS3, PM1, PS2_Moderate, PM2_Supporting, PS4_Supporting. (Bayesian Points: 10; VCEP specifications version 2.3)

Met criteria codes

PS4_Supporting	✔	This variant has been reported in 2 unrelated families meeting Revised Chompret criteria and reported in 1 individual under the age of 40 diagnosed with a HER2+ breast cancer. Based on this evidence, this variant scores 1.5 total points meeting the TP53 VCEP phenotype scoring criteria of 1-1.5 points. (PS4_Supporting; PMIDs: 30455982, 23894400; Internal lab contributors).
PS3	✔	In vitro assays performed in yeast and/or human cell lines showed non-functional transactivation and loss of growth suppression activity indicating that this variant impacts protein function (PS3; PMIDs: 12826609, 30224644, 29979965).
PM2_Supporting	✔	This variant is absent from gnomAD v4.1.0 (PM2_Supporting).
PS2_Moderate	✔	This variant has been identified as a de novo occurrence with confirmed parental relationships in 1 individual with a moderately LFS-associated cancer totaling 2 phenotype points (PS2_Moderate; PMID: 29070607).
PM1	✔	This variant has 11 somatic occurrences for the same amino acid change in cancerhotspots.org (v2) sufficient to be defined as a mutational hotspot by the Clingen TP53 VCEP (≥ 10 somatic occurrences, PMID: 30311369) (PM1).

Not Met criteria codes

PS1	✖	The same amino acid change, resulting from a different nucleotide change c.329_330delinsCC (ClinVar Variation ID: 641505). This variant is considered Pathogenic by one submitter. However, this other variant has not yet been officially curated by the ClinGen TP53 VCEP's specifications (PS1 not met).
BP4	✖	The results from the computational predictors BayesDel and AlignGVGD do not agree, providing no evidence that correlates with a damaging or benign impact on TP53 function via protein change. Additionally, SpliceAI predicts that the variant has no impact on splicing (score threshold ≤ 0.10) (PP3 and BP4 not met).
BP2	✖	Observed at 40% AF in an 80+ yo male w/ pancreatic cancer, possible heme malignancy, and additional TP53 truncating variant subject to NMD, phase unknown, also 40% AF
PP1	✖	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PP3	✖	The results from the computational predictors BayesDel and AlignGVGD do not agree, providing no evidence that correlates with a damaging or benign impact on TP53 function via protein change. Additionally, SpliceAI predicts that the variant has no impact on splicing (score threshold ≤ 0.10) (PP3 and BP4 not met).
PP4	✖	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM6	✖	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline

PM5		✖	1 missense variants in the same codon have been reported (p.Arg110Leu) that is classified as Pathogenic and has lower Grantham score than the variant in question. (PM5 not applied).
BA1		✖	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS2		✖	No cancer free 60+ females in literature or FLOSSIES.
BS1		✖	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS4		✖	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS3		✖	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline

Curation History

Showing 1 to 1 of 1 rows

See Report	Preferred Variant Title	Classification	Condition	Published Date	Version	Criteria Specification	Gene
View	NM_001126112.2(TP53):c.329G>C (p.A...	Pathogenic	Li-Fraumeni Syndrome	2025-07-18	1.0	ClinGen TP53 Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for TP53 Version 2.3.0	TP53

Showing 1 to 1 of 1 rows

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.

ClinGen Terms of Use.

¤ Powered by BCM's Genboree.